Patients who stop taking GLP-1s for pregnancy may be able to resume them while breastfeeding, according to an advisory from the American College of Obstetricians and Gynecologists published Oct. 23.
Under the guidance, OB-GYNs and other healthcare professionals can work with breastfeeding patients to decide whether to include GLP-1s in a postpartum care plan. If the drugs are used, the infant’s weight gain should be closely monitored in coordination with the infant’s healthcare professional. ACOG recommends against GLP-1 use while nursing preterm infants and neonates.
ACOG also advises against GLP-1 use during pregnancy because of a lack of safety data and recommends patients stop taking the drugs one to two months before conception.
Research has found an association between GLP-1 medications, such as Zepbound and Ozempic, and improved reproductive outcomes for women with polycystic ovary syndrome and higher ovulation rates.
“Despite these signals of benefit,” researchers wrote in a July review published in JBRA Assisted Reproduction, GLP-1s “remain contraindicated during pregnancy due to limited human data and fetal risks observed in animal studies; semaglutide and tirzepatide require an 8-10 week washout period prior to conception, and tirzepatide may reduce oral contraceptive effectiveness because of delayed gastric emptying.”
While literature on GLP-1 use during lactation is limited, ACOG said studies suggest the drugs are unlikely to be present in breast milk. Still, people who are breastfeeding should avoid oral GLP-1s because of a lack of safety data on the modifications made to enhance oral absorption, the organization said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
